Tvardi selects ulcerative colitis as first indication for STAT3 inhibitor TTI-109 after positive Phase 1 data

Tvardi Therapeutics, Inc.

TTI-109 Phase 1 healthy volunteer study showed placebo-adjusted reductions in Th17 (up to 76%), Tfh (up to 43%), and B cells (up to 71%) implicated in UC.
Company plans to initiate a Phase 2 study in moderate-to-severe UC in 2027, pending IND clearance and funding.
TTI-109 is an oral small molecule STAT3 inhibitor designed to address immune dysregulation, inflammation, and proliferation.
KOL webinar with Dr. Randy Longman scheduled for August 19, 2026, to discuss UC treatment landscape and TTI-109 data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.